 "Novo Nordisk to invest Euro 100 mn for new facility in France")
Novo Nordisk plans to invest more than Euro 100 million in production facilities at its site in Chartres, France. The expansions will help Novo Nordisk meet the increasing worldwide demand for its diabetes medicines.
The new facility will be built on Novo Nordisk’s existing 31,000 m2 site in Chartres, which produces a range of the company’s insulin products as well as FlexPen, the insulin injection device. The products are exported to more than 40 countries all over the world.
Novo Nordisk has invested Euro 300 million in France over the past 15 years and today employs 1,100 employees at the site. The planned expansion is estimated to create around 250 new jobs once the facilities are fully operational within three to four years.
Lars Rebien Sorensen, president and CEO of Novo Nordisk, “With the coming expansion we will further strengthen Chartres' position in our global product supply organisation.”
The new facility will be built on Novo Nordisk’s existing 31,000 m2 site in Chartres, which produces a range of the company’s insulin products as well as FlexPen, the insulin injection device. The products are exported to more than 40 countries all over the world.
Novo Nordisk has invested Euro 300 million in France over the past 15 years and today employs 1,100 employees at the site. The planned expansion is estimated to create around 250 new jobs once the facilities are fully operational within three to four years.
Lars Rebien Sorensen, president and CEO of Novo Nordisk, “With the coming expansion we will further strengthen Chartres' position in our global product supply organisation.”